Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3

NCT04880395 is registered in ClinicalTrials.gov with Fundación Huésped as lead sponsor.

NCT NCT04880395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3
Lead sponsor
Fundación Huésped
Phase
Phase 4
Overall status
Completed
Start date
May 17, 2021
Completion date
May 7, 2024
Enrollment
265 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection